Funding to drive development of permanent bioelectronic pacemaker following promising clinical data

Ceryx Medical, a UK-based medtech innovator developing next-generation bioelectronic therapies for heart failure, today announced the successful close of a new funding round, bringing the company’s total raised to $15 million. The investment marks a major milestone in Ceryx’s mission to revolutionise cardiac care with intelligent, adaptive pacing technology.

The company’s lead product—a temporary cardiac pacing device—is currently undergoing clinical evaluation. Early results from the ongoing study are highly encouraging, showing the potential to significantly enhance patient recovery following cardiac surgery.

This new funding will accelerate development of Ceryx’s second product: a permanent, physiologically responsive pacemaker designed to provide long-term support for patients with chronic heart failure. Unlike conventional pacemakers, Ceryx’s technology mimics the body’s natural modulation of the heart to deliver real-time, biomimetic pacing, offering a more natural and effective treatment option.

“This investment is a strong endorsement of our team, technology, and vision,” said Stuart Plant, CEO of Ceryx Medical. “The early clinical data from our temporary device has given us real momentum, and with this funding, we’re excited to advance our permanent pacing platform—an innovation that could redefine how heart failure is treated.”

The round was supported by leading investors including BGF, Parkwalk Advisors, Development Bank of Wales (DBW), and BBI, all of whom share Ceryx’s vision for a future where heart failure care is enhanced by intelligent bioelectronic systems.

Spun out of research from the Universities of Bristol, Bath, and Auckland, Ceryx Medical continues to work closely with academic and clinical partners to translate cutting-edge science into life-changing patient outcomes.

About Ceryx Medical

Ceryx Medical is developing a new class of bioelectronic devices that treat heart failure by restoring the body’s natural pacing rhythms. Headquartered in the UK, the company’s mission is to harness the power of biomimicry to improve cardiovascular outcomes and quality of life for millions of patients worldwide.